Ittai Harel

Ittai Harel is a Managing Partner with Pitango Venture Capital, and leads the activity of Pitango HealthTech Fund. His experience includes 25 years of entrepreneurship and executive roles in general management, business development, and marketing with life-science technology companies ranging from digital health, biopharma and medical devices to diagnostics and veterinary health.

Ittai has been leading healthcare and life-science investments at Pitango for the past 16 years, with a focus on Biopharma, Medical Devices, Diagnostics, and Digital Health.

Ittai currently serves on the Board of directors of QuantHealth, ProtAl, Altesa, Homethrive, Surge Therapeutics, Connie Health, TScan(NSDQ:TCRX), Visby, Incredo, Clew Medical, Medisafe, and Vertos Medical

Before joining Pitango, Ittai headed up Corporate Development and Strategy at Nektar Therapeutics (NASDAQ: NKTR) and served as Executive Vice President at IDGene Pharmaceuticals. Prior to this, for 7 years with IDEXX Laboratories (NASDAQ:IDXX) he served in several rolls including as head of business development, corporate development, strategic planning and M&A, and as GM in Europe

Ittai holds a B.Sc. in Chemical Engineering and Biotechnology from Ben Gurion University, and an MSc/MBA from the MIT Sloan School of Management.

LinkedIn profile: linkedin.com/in/ittai-harel-5605787